Nenocorilant features among the latest industry projects newly into phase 1.
ApexOnco Front Page
Recent articles
In fit KMT2Ar patients the group will focus on Revuforj plus Venclexta and azacitidine.
Arcus steps back from TIGIT as its Fc-silent claim crumbles.
The company leaves the door open for Trodelvy pre-chemo, despite Ascent-07’s failure.
Giredestrant’s adjuvant benefit looks similar to that of Kisqali and Verzenio.
Global phase 2 data in TNBC look similar to earlier results in China.
The company might have blown Enliven out of the water.
Studies presented at ASH show this to be true only up to a point.
